NWBO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NWBO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Northwest Biotherapeutics's Enterprise Value is $620.57 Mil. Northwest Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-57.36 Mil. Therefore, Northwest Biotherapeutics's EV-to-EBIT ratio for today is -10.82.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Northwest Biotherapeutics's Enterprise Value is $620.57 Mil. Northwest Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-55.63 Mil. Therefore, Northwest Biotherapeutics's EV-to-EBITDA ratio for today is -11.16.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Northwest Biotherapeutics's Enterprise Value is $620.57 Mil. Northwest Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.93 Mil. Therefore, Northwest Biotherapeutics's EV-to-Revenue ratio for today is 321.21.
The historical data trend for Northwest Biotherapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 146.66 | 1,275.01 | 686.65 | 857.45 | 867.43 |
Northwest Biotherapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Enterprise Value | Get a 7-Day Free Trial | 857.45 | 702.11 | 662.77 | 1,073.02 | 867.43 |
For the Biotechnology subindustry, Northwest Biotherapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Northwest Biotherapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 823.99746 | + | 0 | + | 24.766 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 20.794 | + | 0 | - | 2.126 |
= | 867.43 |
Northwest Biotherapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as
Enterprise Value (Q: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 823.99746 | + | 0 | + | 24.766 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 20.794 | + | 0 | - | 2.126 |
= | 867.43 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics (OTCPK:NWBO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Northwest Biotherapeutics's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 620.570 | / | -57.358 | |
= | -10.82 |
Northwest Biotherapeutics's current Enterprise Value is $620.57 Mil.
Northwest Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-57.36 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Northwest Biotherapeutics's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 620.570 | / | -55.625 | |
= | -11.16 |
Northwest Biotherapeutics's current Enterprise Value is $620.57 Mil.
Northwest Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-55.63 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Northwest Biotherapeutics's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 620.570 | / | 1.932 | |
= | 321.21 |
Northwest Biotherapeutics's current Enterprise Value is $620.57 Mil.
Northwest Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Northwest Biotherapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Navid Malik | director | 1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET |
Marnix L Bosch | officer: Chief Technical Officer | 22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021 |
Alton L Boynton | director, officer: Chief Scientific Officer | 22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021 |
Leslie J. Goldman | officer: See Remarks | C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814 |
Linda F Powers | director, 10 percent owner, officer: President and CEO | 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
Jerry J Jasinowski | director | C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888 |
Jean M. Davis | officer: See Remarks | 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814 |
Susan B Bayh | director | WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Black Cofer | director | 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814 |
Woodford Investment Management Llp | 10 percent owner | 27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX |
Cf Woodford Equity Income Fund | 10 percent owner | C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN |
Cognate Bioservices, Inc. | 10 percent owner | 7513 CONNELLEY DRIVE, HANOVER MD 21076 |
Robert A Farmer | director | 10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154 |
Toucan General Ii, Llc | 10 percent owner | 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
Hemphill Robert F Jr. | 10 percent owner | 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
From GuruFocus
By PRNewswire PRNewswire • 05-30-2022
By PRNewswire • 09-12-2023
By PRNewswire PRNewswire • 03-21-2023
By PRNewswire PRNewswire • 10-28-2021
By PRNewswire PRNewswire • 11-29-2021
By PRNewswire PRNewswire • 06-26-2022
By GF Value GF Value • 04-21-2021
By PRNewswire PRNewswire • 01-06-2023
By PRNewswire PRNewswire • 06-09-2022
By PRNewswire PRNewswire • 06-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.